ArticleCureus2025
Significance of a Three-Missense Pathogenic Variant in the Substrate-Binding Lesion in a Subject With 21-Hydroxylase Deficiency: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Congenital 21-hydroxylase deficiency (21-OHD) represents a healthcare challenge during the transition from childhood to adulthood for young adults with special needs. Although numerous countries have implemented newborn screening programs for 21-OHD, a significant number of patients may reach adulthood without undergoing genetic testing. In this report, we present a case of a 26-year-old Japanese woman with 21-OHD, who was referred to our hospital for the transition from childhood to adulthood in young adults with special healthcare needs (YASHCN). At that time, she had no complaints, but she wanted to undergo a thorough examination for a correct diagnosis of 21-OHD. The genetic test showed a novel new variant of the three-cluster mutation, p.[Ile237Lys; Val238Glu; Met240Lys]. Our findings highlight the significance and reaffirmation of the three-missense pathogenic variant in the CYP21A2 gene in determining the enzyme activity of 21-hydroxylase and the onset of 21-OHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.